Treatment of severe refractory psoriasys with infliximab. Clinical outcomes after one of therapy [3];Tratamiento de la psoriasis extensa y refractaria con infliximab. Resultados tras un ano de tratamiento

Medicina Clinica

Volumn 125, Issue 4, 2005, Pages 159-

  Mahiques Santas, Laura ^a   Martínez Menchon, Teresa ^a   Sánchez Carazo, José Luis ^a   Fortea Baixauli, José Miguel ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE;

LETTER; PSORIASIS; REFRACTORY PERIOD; TREATMENT OUTCOME;

EID: 23044454431     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076946     Document Type: Letter

References (7)

1. Mahiques Santos L, Martínez-Menchón T, Sánchez Carazo JL, Oliver Martínez V, Soriano Navarro CJ, Fortea Baixauli JM. Tratamiento de la psoriasis extensa y refractaria con infliximab. Med Clin (Barc). 2004;123:657-8.
2. Hanaver SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
3. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49:112S-7S.
4. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor a, infliximab. J Am Acad Dermatol. 2002;46:886-91.
5. Chaudhari U, Romano P, Mulcahy D, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-7.
6. Gottlieb AB, Chaudhary U, Mulcahy L, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48:829-35.
7. Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin. 2004;22:427-35.